ADAM17 expression in ACEI/ARB-treated patients with hypertension was comparable to that observed in patients without hypertension
- 27 April 2026
- journal article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (9) , 1061-1066
Abstract
Background: ADAM17 (A disintegrin and metalloproteinase 17) contributes to angiotensin-converting enzyme (ACE) 2 shedding in response to angiotensin II–AT1 receptor signaling, potentially shifting the renin–angiotensin system toward its pressor arm. We investigated whether ACE inhibitor (ACEI) or AT1 receptor blocker (ARB) therapy modulates ADAM17 expression. Methods: ADAM17 protein expression was evaluated by immunohistochemistry in alveolar type II pneumocytes of lung parenchymal samples from untreated control patients (n = 20) and patients treated with ACEI (n = 21) or ARB (n = 17; total ACEI/ARB-treated patients = 38). Results: There were no significant differences in the proportion of ADAM17-expressing type II pneumocytes between patients without hypertension and ACEI/ARB-treated patients with hypertension (56.1 ± 4.3% vs. 45.8 ± 3.1%, respectively). Similarly, no differences were observed according to smoking status (50.6 ± 4.1% in never smokers, 48.4 ± 4.0% in current smokers, and 50.8 ± 6.8% in former smokers) or sex (49.7 ± 4.2% in women vs. 49.1 ± 3.3% in men). In contrast, a significant age-related decline in the proportion of ADAM17-expressing type II pneumocytes was observed (56.2 ± 3.5% in patients <60 years vs. 43.0 ± 3.5% in patients ≥60 years; P = .005). Conclusions: These findings suggest that ACEI/ARB therapy, while targeting the pressor axis of the RAS, maintains ADAM17 expression at levels comparable to those in patients without hypertension. ACEI/ARB therapy may represent a potential strategy for the treatment of ADAM17-mediated cardiovascular, pulmonary, and inflammatory diseases.Keywords
Funding Information
- Universidad de Buenos Aires (UBACYT 2020 20020190100030BA)
- Consejo Nacional de Investigaciones Científicas y Técnicas (ANPCYT (PICT 2019-2384))
This publication has 21 references indexed in Scilit:
- The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyondThe FEBS Journal, 2023
- miR-145 Alleviates Smooth Muscle Cell Phenotype Transition via ADAM17-Mediated ACE2 SheddingInternational Journal of Hypertension, 2023
- A structural model of the iRhom–ADAM17 sheddase complex reveals functional insights into its trafficking and activityCellular and Molecular Life Sciences, 2023
- The collectrin‐like part of the SARS‐CoV‐1 and ‐2 receptor ACE2 is shed by the metalloproteinases ADAM10 and ADAM17The FASEB Journal, 2022
- Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytesLife Sciences, 2022
- Lung ACE2 and ADAM17 in pulmonary arterial hypertension: Implications for COVID-19?The Journal of Heart and Lung Transplantation, 2020
- Decreased ADAM17 expression in the lungs of α-Klotho reduced mouseThe Journal of Biochemistry, 2020
- A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on PerindoprilCardiology and Therapy, 2019
- Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissueScientific Reports, 2016
- Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lungVirchows Archiv, 2009